CytoDyn Inc. Form 8-K (March 8, 2021)
Summary
Form 8-K current report of CytoDyn Inc., SEC File Number 000-49908, dated March 8, 2021. Under Item 7.01 it furnishes, as Exhibit 99.1, the company's Executive Summary of data from its Phase 2b/3, two-arm, randomized, double-blind, placebo-controlled trial of the investigational drug leronlimab as add-on therapy for severe-to-critical COVID-19 patients receiving institutional standard of care. The report states the information is furnished, not filed, for purposes of Section 18 of the Exchange Act. It is signed by Michael D. Mulholland, Chief Financial Officer.
Summary drafted by a model from the document's text below and checked by script against that text before publication. It is a navigation aid, not a reading of what the document proves. Where AI is used
Cite this document
“CytoDyn Inc. Form 8-K (March 8, 2021).”
Original at www.sec.gov. Archived at Pandemic Darlings, https://pandemicdarlings.com/source-documents/sec-cydy-8-k-filed2021-03-08-0001193125-21-073448-3a6fb8c5a1/
, SHA-256 de815c742a33254803f12cd0375e8c0c5c990a46f4b49d9c89a2bfab9e099e9b.Full text
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): March 8, 2021 CytoDyn Inc. (Exact name of registrant as specified in its charter) Delaware | 000-49908 | 83-1887078 (State or other jurisdiction of incorporation) | (SEC File Number) | (I.R.S. Employer Identification No.) 1111 Main Street , Suite 660 Vancouver , Washington 98660 (Address of principal executive offices) (360) 980-8524 Registrant’s telephone number, including area code: Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below): ☐ | Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) ☐ | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) ☐ | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) ☐ | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) Securities registered pursuant to Section 12(b) of the Act: Title of each class | Trading Symbol(s) | Name of each exchange on which registered None. | None. | None. Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging growth company ☐ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐ Item 7.01 | Regulation FD Disclosure Attached as Exhibit 99.1 is a copy of CytoDyn Inc.’s Executive Summary of the data from its Phase 2b/3, two-arm, randomized, double-blind, placebo-controlled trial to evaluate its investigational drug leronlimab’s safety and efficacy as add-on therapy in patients being treated with institutional standard of care for severe-to-critical COVID-19 patients. The information in this Current Report on Form 8-K and in Exhibit 99.1 is being furnished pursuant to Item 7.01 and shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934 (the “Exchange Act”) or otherwise subject to the liabilities of that section, nor shall it be deemed to be incorporated by reference in any filing under the Securities Act of 1933 or the Exchange Act. Item 9.01. | Financial Statements and Exhibits. (d) Exhibits Exhibit No. | Description 99.1 | Executive Summary of CD12 COVID-19 Study Data 104 | Cover Page Interactive Data File (formatted as Inline XBRL) SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized. CytoDyn Inc. Dated: March 8, 2021 | By: | /s/ Michael D. Mulholland Michael D. Mulholland Chief Financial Officer
File and source
- File
- SEC_CYDY_8-K_filed2021-03-08_0001193125-21-073448.htm
- Size
- 24,392 bytes
- SHA-256
- de815c742a33254803f12cd0375e8c0c5c990a46f4b49d9c89a2bfab9e099e9b
- Original
- www.sec.gov